BC Week In Review | Apr 28, 2014
Clinical News

AdipoCell: Clinical trial started

Bioheart began an open-label, U.S. clinical trial to evaluate IV AdipoCell in up to 100 patients with COPD. Bioheart is evaluating AdipoCell in a Phase I trial in patients with degenerative disc disease and has...
BC Week In Review | Apr 14, 2014
Clinical News

AdipoCell: Clinical trial started

Bioheart began an open-label, U.S. clinical trial to evaluate intra-discally injected AdipoCell in up to 100 patients with degenerative disc disease. AdipoCell has completed a Phase I trial for congestive heart failure (CHF). Last year,...
BC Week In Review | Mar 24, 2014
Clinical News

AdipoCell: Additional Phase I data

Additional data from the Mexican Phase I ANGEL trial in 5 CHF patients showed that AdipoCell injection led to an average improvement of 6MWT of 68 meters from baseline to 6 months. Additionally, 80% of...
BC Week In Review | Mar 24, 2014
Company News

Bioheart, Magnum Cell Therapies deal

Bioheart partnered with Magnum to provide Bioheart's autologous cellular therapies to patients living in Honduras as well as to medical tourists. Bioheart will provide training to Magnum and will take a 10% ownership stake in...
BC Week In Review | Nov 11, 2013
Company News

Bioheart, Global Stem Cells Group Inc. sales and marketing update

The companies partnered to provide Bioheart's therapies and products to Global Stem's network of physicians and qualified patients. Under the deal, Global Stem will also train additional physicians in Bioheart's regenerative medicine techniques while contributing...
BC Week In Review | Oct 14, 2013
Clinical News

Adipose-derived stem cells: Preliminary Phase I data

Preliminary data from the Mexican Phase I ANGEL trial in 5 CHF patients showed that AdipoCell injection was safe and led to an average improvement in 6MWT of 47 meters from baseline to 3 months....
BC Week In Review | Sep 30, 2013
Company News

Bioheart, Invitrx deal

Invitrx granted Bioheart rights to Invitrx's adipose derived stem cell products for use in all indications in humans and animals. Bioheart intends to use these techniques to advance the development and commercialization of its AdipoCell...
BC Week In Review | Jun 17, 2013
Clinical News

LipiCell: Completed Phase I enrollment

Bioheart said it completed enrollment and treated all CHF patients in the Mexican Phase I ANGEL trial evaluating LipiCell. Bioheart Inc. (OTCBB:BHRT), Sunrise, Fla.   Product: LipiCell , Adipose-derived stem cells (ADSC)   Business: Cardiovascular  ...
BC Week In Review | Jun 10, 2013
Clinical News

LipiCell: Phase I started

Bioheart began the Mexican Phase I ANGEL trial to evaluate LipiCell in 5 CHF patients. Bioheart Inc. (OTCBB:BHRT), Sunrise, Fla.   Product: LipiCell , Adipose-derived stem cells (ADSC)   Business: Cardiovascular   Molecular target: NA  ...
BC Week In Review | Feb 27, 2012
Company News

Bioheart, Ageless Regenerative Institute deal

The institute granted Bioheart exclusive, worldwide rights to LipiCell adipose-derived stem cell technology to treat heart attack and heart failure. The institute will receive an upfront payment and milestones. Bioheart is conducting a Phase I/II...
Items per page:
1 - 10 of 10